AvalehtATBPF • OTCMKTS
add
Antibe Therapeutics, Inc.
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (CAD) | dets 2023info | Y/Y muutus |
|---|---|---|
Käive | — | — |
Põhitegevusega seonduv kulu | 4,60 mln | — |
Puhastulu | −4,21 mln | — |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | −0,08 | −32,96% |
EBITDA | — | — |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (CAD) | dets 2023info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 24,91 mln | — |
Kogu vara | 56,36 mln | — |
Kõik kohustused | 30,42 mln | — |
Kogu omakapital | 25,94 mln | — |
Emiteeritud aktsiate arv | 52,67 mln | — |
Hinna ja väärtuse suhe P/B | 0,44 | — |
Varade tasuvus | −19,71% | — |
Kapitali tasuvus | −41,30% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (CAD) | dets 2023info | Y/Y muutus |
|---|---|---|
Puhastulu | −4,21 mln | — |
Põhitegevuse rahakäive | −3,84 mln | — |
Investeeringute raha | 11,04 mln | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | 7,20 mln | — |
Tasuta rahavoog | −2,47 mln | — |
Teave
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Asutatud
2009
Veebisait
Töötajate arv
11
